Tongling Bionic IABP Makes Debut at MCS Training Class

Recently, the Mechanical Circulatory Support Training Class for Advanced Chest Pain Centers (First Session), hosted by the Suzhou Industrial Park Oriental Huaxia Cardiovascular Health Institute and organized by Zhongshan Hospital affiliated to Fudan University, was successfully concluded. During the two-day training, nearly 100 medical professionals from multiple hospitals across the country gathered to participate in a series of specialized presentations and technical explanations.

The training program invited several experts from Zhongshan Hospital to provide systematic explanations on mechanical circulatory support technologies, including percutaneous ventricular assist devices (pVAD), extracorporeal membrane oxygenation (ECMO), and intra-aortic balloon pumps (IABP). They elaborated on the working principles, clinical indications, practical application scenarios, and latest advancements of these technologies. From a clinical practice perspective, the experts particularly emphasized the critical value of IABP in treating severe cardiac critical conditions.

IABP primarily provides hemodynamic support for critically ill cardiac patients. Its indications include acute coronary syndrome, cardiac and non-cardiac surgeries, and complications of heart failure. It is routinely equipped in cardiac catheterization laboratories in China as essential circulatory support emergency equipment.

With advantages such as rapid deployment, user-friendly operation, proven efficacy, and minimal complications, IABP has been widely adopted in clinical practice and has received recommendations from numerous international and domestic guidelines and consensus documents. For example, the 2025 American "ACC/AHA/ACEP/NAEMSP/SCAI Guidelines for Acute Coronary Syndromes" state that short-term mechanical circulatory support devices are reasonable for hemodynamic stabilization as a bridge to surgery in ACS patients with mechanical complications. Similarly, China's "Percutaneous Coronary Intervention Guidelines" released the same year also provide clear recommendations for its use.

After years of technological breakthroughs, Tongling Bionic has successfully launched China's first IABP device (Model: TL-IABP-100) and intra-aortic balloon pump catheter kits (Models: TL-IAB-30, TL-IAB-40). Developed in accordance with leading domestic standards, the products integrate recent technological achievements and feature continuous innovations in pneumatic systems, intelligent algorithms, software functionality, and balloon performance. These advancements effectively enhance the precision of counterpulsation therapy and clinical benefits, providing patients with superior hemodynamic support.

During the training session, experts from Zhongshan Hospital conducted live demonstrations of the Tongling Bionic IABP device's operational procedures and balloon placement steps, while also sharing key considerations based on clinical experience. The medical professionals engaged in simulation exercises and provided positive feedback on the product.

The percutaneous ventricular assist device (pVAD) represents one of the most advanced mechanical circulatory support technologies currently available. By implanting a miniature axial-flow pump into the heart, it continuously pumps blood from the ventricle into the artery, actively reducing cardiac workload.

Tongling Bionic has developed multiple product models, including the TeleVad P35 and P50. The company has achieved a series of breakthroughs in key technologies such as hemodynamic optimization and blood damage profile refinement, as well as in the design and manufacturing of core components like micro-motors, low-hemolysis impellers, and novel anticoagulation and cooling systems. These innovations are supported by fully independent intellectual property rights. The products have been selected for the National Key R&D Program and entered the special review process for innovative medical devices under the National Medical Products Administration.

With the intensification of population aging, the prevention, control, and treatment of cardiovascular diseases remain challenging, necessitating more comprehensive and accessible solutions. Tongling Bionic is committed to becoming an integrated solutions provider for the entire heart failure lifecycle. Moving forward, the company will continue to focus on clinical needs, drive product innovation, and support the expansion of high-quality medical resources to benefit more healthcare institutions and patients.